Catalyst Pharmaceuticals (CPRX) Tops Q3 EPS by 8c; Offers FY22 Revenue Guidance
Tweet
Share
E-mailGet Alerts CPRX Hot Sheet
Price: $31.49 --0%
Financial Fact:
Loss from operations: -3.91M
Today's EPS Names:
SVBT, ZEO, OTLK, More
Financial Fact:
Loss from operations: -3.91M
Today's EPS Names:
SVBT, ZEO, OTLK, More
Join SI Premium – FREE
Catalyst Pharmaceuticals (NASDAQ: CPRX) reported Q3 EPS of $0.26, $0.08 better than the analyst estimate of $0.18. Revenue for the quarter came in at $57.2 million versus the consensus estimate of $53.62 million.
GUIDANCE:
Catalyst Pharmaceuticals sees FY2022 revenue of $205-210 million, versus the consensus of $205 million.
For earnings history and earnings-related data on Catalyst Pharmaceuticals (CPRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
- Edible Garden AG (EDBL) Reports Q2 Loss of $18.79
- Zeo Energy Corp (ZEO) Misses Q2 EPS by 7c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
